ScholarLens Back to search
2018•British Journal of DermatologyRequires access

Drug survival of secukinumab for moderate-to-severe plaque psoriasis: reply from authors

Alexander Egeberg, Lone Skov

Open publisher page 2 citations

Abstract

Linked Article:Egeberg et al. Br J Dermatol 2018; 178:509–19.

About this research paper

What this paper is about

Linked Article:Egeberg et al. Br J Dermatol 2018; 178:509–19.

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Linked Article:Egeberg et al. Br J Dermatol 2018; 178:509–19.

Key concepts: Secukinumab, Plaque psoriasis, Medicine, Dermatology, Psoriasis, Drug, Pharmacology, Psoriatic arthritis

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
Drug survival of secukinumab for moderate-to-severe plaque psoriasis: reply from authors — Research Paper | ScholarLens